Fig. 2

Study design. At the start of the treatment patients receive adjuvant hormone therapy (ADT) at most one month prior to the start of external beam radiation therapy (EBRT) and will continue during EBRT. Adjuvant hormone therapy is then continued as adjuvant treatment up to the advised total duration of 3 years (provided that its toxicity remains acceptable). In week two of EBRT, patients also receive one concurrent cycle of systemic [¹⁷⁷Lu]Lu-PSMA-617 (Lu-PSMA) as part of the study procedure